
Immunovant Inc (IMVT) Stock Forecast & Price Target
Immunovant Inc (IMVT) Analyst Ratings
Bulls say
Immunovant Inc. has demonstrated a significant potential in the treatment of autoimmune diseases, particularly through its lead candidate IMVT-1402, which has shown a sustained reduction in thyroid-stimulating hormone receptor autoantibodies (TRAb) during the off-treatment period. The data indicates an impressive responder rate of 81% among patients who did not respond to antithyroid drug therapy, aligning closely with the treatment's active phase responder rates of 70%-80%, thereby underscoring the therapeutic and disease-modifying capabilities of FcRn blockers in this patient population. This strong clinical performance highlights the durability of the treatment's effects, reinforcing a positive outlook on Immunovant's stock as it advances its innovative immunology solutions.
Bears say
Immunovant Inc operates in a competitive clinical-stage immunology market, focusing on developing IMVT-1402 to combat autoimmune diseases linked to elevated levels of pathogenic immunoglobulin G antibodies. However, high levels of thyrotropin receptor antibodies (TRAbs) have been correlated with increased relapse rates, indicating potential limitations in the efficacy of their product candidate. Additionally, the interconnectedness of TRAbs with TSHR and IGF-1R receptors may lead to severe complications, underscoring significant challenges in achieving therapeutic success and raising concerns about the company's future financial viability.
This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunovant Inc (IMVT) Analyst Forecast & Price Prediction
Start investing in Immunovant Inc (IMVT)
Order type
Buy in
Order amount
Est. shares
0 shares